B-ALL
Clinical trials for B-ALL explained in plain language.
Never miss a new study
Get alerted when new B-ALL trials appear
Sign up with your email to follow new studies for B-ALL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to boost CAR t-cell success in hard-to-treat blood cancers
Disease control Recruiting nowThis early-phase study tests a radioactive drug (131-I apamistamab) given before CAR T-cell therapy for people with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma. The goal is to find a safe dose and see if the combination is tolera…
Matched conditions: B-ALL
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
Double-Targeting CAR T-Cells offer new hope for kids with relapsed leukemia
Disease control Recruiting nowThis study tests a new treatment for children and young adults (ages 3-39) with B-cell leukemia or lymphoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to target two cancer proteins (CD19 …
Matched conditions: B-ALL
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC
-
Engineered immune cells take aim at childhood leukemia in new trial
Disease control Recruiting nowThis early-phase trial tests a new treatment called CD123-CAR T cells for children and young adults (up to age 21) with certain types of leukemia or related blood cancers that have come back or not responded to standard therapy. The treatment involves collecting the patient's own…
Matched conditions: B-ALL
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New immune cell therapy targets Hard-to-Treat leukemia in early trial
Disease control Recruiting nowThis early-phase trial tests a new treatment called CD19 t-hANK for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back after previous treatments. The therapy uses specially designed immune cells to attack cancer cells. Up to 10 participant…
Matched conditions: B-ALL
Phase: PHASE1 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
New CAR T-Cell therapy aims to stop leukemia relapse after first treatment
Disease control Recruiting nowThis study tests whether a second type of CAR T-cell therapy, targeting CD22, can keep acute lymphoblastic leukemia (ALL) from coming back in people who already had CD19 CAR T-cell treatment. About 20 children and adults aged 3 to 65 who show no signs of cancer after their first …
Matched conditions: B-ALL
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
New injection targets tough leukemia in early trial
Disease control Recruiting nowThis early-stage study is testing a new drug, KSV01, in 30 adults with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments. The main goal is to check if the drug is safe and tolerable, and to find the right dose. Researchers will also lo…
Matched conditions: B-ALL
Phase: PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
New hope for leukemia patients: CAR-T cells vs. standard donor infusion in Head-to-Head trial
Disease control Recruiting nowThis study tests whether a personalized CAR-T cell therapy works better than standard donor immune cells (DLI) to eliminate leftover leukemia cells in 70 patients who had a stem cell transplant. Participants must have a specific type of B-cell leukemia with minimal residual disea…
Matched conditions: B-ALL
Phase: PHASE3 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 11, 2026 12:12 UTC
-
New CAR-T therapy offers hope for young patients with Tough-to-Treat leukemia
Disease control Recruiting nowThis study is testing a new treatment called Senl_B19 CAR-T cells for children and young adults (ages 3 to 25) with a type of blood cancer called B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments. The therapy uses the patient's own imm…
Matched conditions: B-ALL
Phase: PHASE2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Jun 08, 2026 13:11 UTC
-
New monitoring strategy aims to predict relapse after CAR T-Cell therapy in kids
Knowledge-focused Recruiting nowThis study is testing whether frequent blood and bone marrow tests can help doctors know which children with B-cell acute lymphoblastic leukemia (B-ALL) are cured by CAR T-cell therapy alone and which might need a stem cell transplant. About 60 participants aged 1 to 25 who have …
Matched conditions: B-ALL
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:08 UTC
-
New study tracks hidden dangers of CAR t therapy in kids
Knowledge-focused Recruiting nowThis study follows 100 children and young adults who received CAR T cell therapy to understand short- and long-term side effects like infections, slow blood cell recovery, and nerve problems. Researchers will check participants at 3, 6, 12, and 24 months after treatment. The goal…
Matched conditions: B-ALL
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:03 UTC